Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-05-22
2010-11-02
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S570000, C514S613000
Reexamination Certificate
active
07825107
ABSTRACT:
A method for treatment or prevention of chronic nonbacterial prostatitis in individuals without urethral sphincter dysfunction, comprises administering an effective amount of (i) a selective estrogen receptor modulator (SERM) having estrogen antagonist effect in the prostate, (ii) an aromatase inhibitor, and/or (iii) an antiestrogen.
REFERENCES:
patent: 4536516 (1985-08-01), Harper et al.
patent: 4656187 (1987-04-01), Black et al.
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4839155 (1989-06-01), McCague
patent: 4894373 (1990-01-01), Young
patent: 4977906 (1990-12-01), Di Scipio
patent: 4996225 (1991-02-01), Toivola et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5192525 (1993-03-01), Yang et al.
patent: 5196435 (1993-03-01), Clemens et al.
patent: 5446203 (1995-08-01), McNelis
patent: 5470883 (1995-11-01), Stromberg
patent: 5491173 (1996-02-01), Toivola et al.
patent: 5658931 (1997-08-01), Bryant et al.
patent: 5691355 (1997-11-01), Bryant et al.
patent: 5693674 (1997-12-01), Bitonti
patent: 5703109 (1997-12-01), Karjalainen et al.
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 5750576 (1998-05-01), DeGregorio et al.
patent: 5807899 (1998-09-01), Bohlmann et al.
patent: 5821254 (1998-10-01), Sporn et al.
patent: 5827892 (1998-10-01), Löser et al.
patent: 5852059 (1998-12-01), Thompson
patent: 5861389 (1999-01-01), Radlmaier et al.
patent: 5877219 (1999-03-01), Willson
patent: 5912273 (1999-06-01), Degregorio et al.
patent: 5972921 (1999-10-01), Santi et al.
patent: 6037379 (2000-03-01), Härkönen et al.
patent: 6316431 (2001-11-01), Santti et al.
patent: 6576645 (2003-06-01), Södervall et al.
patent: 6608111 (2003-08-01), Meyers et al.
patent: 6686351 (2004-02-01), Bhagwat
patent: 6875775 (2005-04-01), Södervall et al.
patent: 0 095 875 (1983-12-01), None
patent: 0 779 808 (1999-08-01), None
patent: 1 199 069 (2002-04-01), None
patent: 1064629 (1967-04-01), None
patent: WO 92/06068 (1992-04-01), None
patent: WO 93/19746 (1993-10-01), None
patent: WO 94/13645 (1994-06-01), None
patent: WO 95/26720 (1995-10-01), None
patent: WO 96/07402 (1996-03-01), None
patent: WO 9609057 (1996-03-01), None
patent: WO 96/35417 (1996-11-01), None
patent: WO 96/40616 (1996-12-01), None
patent: WO 97/26876 (1997-07-01), None
patent: WO 97/32574 (1997-09-01), None
patent: WO 98/11888 (1998-03-01), None
patent: WO 99/42427 (1999-08-01), None
patent: WO 99/42427 (1999-08-01), None
patent: WO 99/63974 (1999-12-01), None
patent: WO 00/55137 (2000-09-01), None
patent: WO 01/36360 (2001-05-01), None
patent: WO 02/03989 (2002-01-01), None
patent: WO 03/039524 (2003-05-01), None
Harkonen et al., The Journal of Steroid Biochemistry & Molecular Biology, 2004;92:297-305.
Bentrem, D.J., et al., “Tamoxifen, raloxifene and the prevention of breast cancer”, Minerva Endocrinologica, vol. 27, No. 2, 2002, pp. 127-139.
Budavari, S. et al., eds.,The Merck Index, Eleventh Edition, p. 1430, No. 9019, Merck & Co., Inc., Rathway, NJ, USA (1989).
Budavari, S. et al., eds.,The Merck Index, Eleventh Edition, p. 1433, No. 9039, Merck & Co., Inc., Rathway, NJ, USA (1989).
de Lignieres, B., “Transdermal Dihydrotestosterone Treatment of Andropause,” 25Ann Med235-241 (1993).
Doran, P.M., “Effects of Raloxifene, a Selective Estrogen Receptor Modulator, on Bone Turnover Markers and Serum Sex Steroid and Lipid Levels in Elderly Men”, Journal of Bone and Mineral Research, vol. 16, No. 11, 2001, pp. 2118-2125.
Gingell, J.G., et al., “Placebo Controlled Double-Blind Study to Test the Efficacy of the Aromatase Inhibitor Atamestane in Patients with Benign Prostatic Hyperplasia not Requiring Operation,”J. Urol. 154:399-401 (Aug. 1995).
Glass, A.R., MD “Gynecomastia,” 23Clinical Andrology825-837 (Dec. 1994).
Goldstein, S.R. et al., “A pharmacological review of selective oestrogen receptor modulators,”Human Reproduction Update6:212-224, Oxford University Press (May-Jun. 2000).
Grodstein, F. and Stampfer, M.J., “Estrogen for women at varying risk of coronary disease,”Maturitas30:19-26, Elsevier Science Ireland Ltd. (1998).
Hakenberg, O.W., et al., “Chronic Pelvic Pain in Men,”Urol. Intl. 68:138-143 (2002).
Henderson, V.W., “Estrogen, Cognition, and a Woman's Risk of Alzheimer's Disease,”The American Journal of Medicine103:115-185, Excerpta Medica, Inc. (1997).
International Search Report for corresponding International Application No. PCT/FI00/00946, mailed Feb. 8, 2001.
Jordan, V.C., “Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents,”J. Med. Chem. 46(7):1081-1111 (Mar. 2003).
Kangas, L. et al., “A new triphenylethylene compound, Fc-1157a: II. Anti effects,”Cancer Chemother. Pharmacol. 17:109-113, Springer-Verlag (1986).
Kangas, L. et al., “Bioluminescence of Cellular ATP: A New Method for Evaluating Cytotoxic Agents In Vitro,”Medical Biology62:338-343, Duodecim (1984).
Kangas, L., “Biochemical and Pharmacological Effects of Toremifene Metabolites,”Cancer Chemo. Pharmacol. 27:8-12 (Apr. 1990).
Karjalainen, A. et al. (2000). “Synthesis of new potent and selective aromatase inhibitors based on long-chained diarylalkylimidazole and diarylalkyltriazole molecule skeletons,”Eur. J. Pharm. Sci. 11:109-131.
Khovidhunkit, W. and Shoback, D.M., “Clinical Effects of Raloxifene Hydrochloride in Women,”Ann. Intern. Med. 130:431-439, American College of Physicians (Mar. 1999).
Licata, A.A., et al., “Raloxifene: A new choice for treating and preventing osteoporosis”, Osteoporosis Update reprinted from Cleveland Clinic Journal of Medicine, vol. 67, No. 4, Apr. 2000, pp. 273-280, reprinted as pp. 19-26.
Lobo, R.A., “Benefits and risks and estrogen replacement therapy,”Am. J. Obstet. Gynecol. 173:982-989, Mosby-Year Book, Inc. (1995).
Macgregor, J.I. and Jordan, V.C., “Basic Guide to the Mechanisms of Antiestrogen Action,”Pharmacol. Rev. 50:151-196, Williams and Wilkins Co. (1998).
Oesterling, J.E. et al. (1988) “Aromatase Inhibition in the DOG. II. Effect on Growth, Function, and Pathology of the Prostate”, The Journal of Urology, vol. 139 Apr.:832-839.
Peng, Z. et al., “The Mechanical Strength of Bone in Different Rat Models of Experimental Osteoporosis,”Bone15:523-532, Elsevier Science Ltd. (1994).
Plouffe, L., “Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice,”J. Soc. Gynecol. Investig. 7:S38-S46, Elsevier Science Inc. (Jan.-Feb. 2000).
Qu, Q. et al., “Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats,”Endocrinology14:809-820, Association for the Study of Internal Secretions (Fed. 2000).
Radlmaier A. et al., “Estrogen Reduction by Aromatase Inhibition for Benign Prostatic Hyperplasia: Results of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial Using Two Doses of the Aromatase-Inhibitor Atamestane,”The Prostate29:199-208 (1996).
Renaud, J., et al., “Estrogen Receptor Modulators: Identification and Structure—Activity Relationships of Potent Erα-Selective Tetrahydroisoquinoline Ligands”, J. Med. Chem., vol. 46, 2003, pp. 2945-2957.
Robinson, D., et al., “Overactive Bladder in the Female Patient: The Role of Estrogens”, Current Urology Reports, vol. 3, 2002, pp. 452-457.
Robinson, D., et al., “The Role of Estrogens in Female Lower Urinary Tract Dysfunction”, Urology, vol. 62, Supp. 4A, Oct. 2003, pp. 45-50.
Santti et al.; Final Office Action from U.S. Appl. No. 10/454,823, filed Jun. 5, 2003.
Schilcher, H., “Miktionsbeeinflussende Mittel zur Behandlung der BPH,”Phytotherapie in der Urologie69-93 (1992).
Shuk-Mei Ho, “Estrogens and Anti-Estroge
Bernoulli Jenni
Santti Risto
Streng Tomi
Yatkin Emrah
Brinks Hofer Gilson & Lione
Hormos Medical Ltd.
Hui San-ming
LandOfFree
Method of treating men suffering from chronic nonbacterial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating men suffering from chronic nonbacterial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating men suffering from chronic nonbacterial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240097